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Barrier Disruption and Hemorrhagic
Transformation Following Ischemic
Stroke
Renée J. Turner 1* and Frank R. Sharp 2
1Discipline of Anatomy and Pathology, Adelaide Centre for Neuroscience Research, School of Medicine, The University of
Adelaide, Adelaide, SA, Australia, 2Department of Neurology, MIND Institute, University of California at Davis Medical Center,
Sacramento, CA, USA
Numerous studies have documented increases in matrix metalloproteinases (MMPs),
specifically MMP-9 levels following stroke, with such perturbations associated with
disruption of the blood brain barrier (BBB), increased risk of hemorrhagic complications,
and worsened outcome. Despite this, controversy remains as to which cells release
MMP-9 at the normal and pathological BBB, with even less clarity in the context of
stroke. This may be further complicated by the influence of tissue plasminogen activator
(tPA) treatment. The aim of the present review is to examine the relationship between
neutrophils, MMP-9 and tPA following ischemic stroke to elucidate which cells are
responsible for the increases in MMP-9 and resultant barrier changes and hemorrhage
observed following stroke.
Keywords: neutrophils, MMP-9, tPA, blood-brain barrier, ischemic stroke, hemorrhagic transformation, cerebral
edema
INTRODUCTION
Over the last decade the matrix metalloproteinases (MMPs) have been widely investigated for their
role in disruption of the blood-brain barrier (BBB), particularly the extracellular matrix (ECM),
following stroke (Romanic et al., 1998; Rosenberg et al., 1998; Fujimura et al., 1999; Gasche et al.,
1999; Gidday et al., 2005) and other cerebral pathologies such as traumatic brain injury (Planas
et al., 2001) and neoplasm (Lukes et al., 1999; Turba et al., 2007). MMPs are a family of zinc
and calcium-dependent endopeptidases that are capable of degrading all components of the ECM
including laminin, collagen and fibronectin, amongst many other targets (Van den Steen et al.,
2002). At least 23MMPs have been identified to date (Sternlicht andWerb, 2001), withMMP-2 and
MMP-9 the most widely studied in stroke. In particular, MMP-9 has been implicated, not only in
the pathogenesis of BBB breakdown and subsequent vasogenic edema formation following stroke
(Fujimura et al., 1999; Gasche et al., 1999; Rosenberg and Yang, 2007), but also in hemorrhagic
transformation (HT) in the setting of tissue plasminogen activator (tPA) therapy (Lapchak et al.,
2000; Wang et al., 2009). Cerebral edema and HT of the infarct are significant problems in clinical
stroke, which are associated with poor outcome and contribute to the morbidity and mortality
of this condition (Hacke et al., 1996; Fiorelli et al., 1999). Elucidating the mechanisms of such
deleterious events is the key to developing targeted, more effective clinical therapies.
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Numerous clinical and experimental studies have confirmed
an increase in serum MMP-9 following stroke (Clark et al.,
1997; Romanic et al., 1998; Yushchenko et al., 2000; Montaner
et al., 2003a; Ning et al., 2006). However, the cellular source
of this MMP-9 remains controversial. Although it is generally
accepted that MMP-9 is increased following stroke, there is
debate as to which cells are responsible, whether it be resident
brain cells, cells of the vasculature or circulating immune cells,
such as neutrophils. However, the aim of the present review
was to explore the potential relationship between neutrophil-
derived MMP-9 and complications such as BBB disruption and
HT following stroke to elucidate the cellular source of MMP-9 in
ischemic stroke.
Matrix Metalloproteinases
MMPs regulate many aspects of cellular activity with functions
ranging from ECM degradation, cell proliferation, adhesion,
and migration to release of ECM-sequestered molecules by
proteolysis, shedding of cell-surface proteins that transduce
signals from the ECM (Cunningham et al., 2005) and activation
of pro-inflammatory cytokines (Candelario-Jalil et al., 2009).
As such, recognized targets of MMP-9 include components of
the ECM, tight junction components, growth factors and their
precursors, cell surface receptors and cell adhesion molecules
(Bajor and Kaczmarek, 2013; Vandooren et al., 2013; Conant
et al., 2015). The MMPs may have pleiotropic actions on target
tissues, with MMPs integrally involved in the normal remodeling
of tissue during development and homeostasis but dysregulation
of MMPs is implicated in disease states and has repercussions for
BBB integrity, tissue injury and cell death (Agrawal et al., 2008).
However, action of the MMPs, including MMP-9, have been well
documented to play critical roles in tissue repair and remodeling
following stroke (Lenglet et al., 2015), particularly in angiogenesis
and re-establishment of cerebral blood flowwith long-termMMP
inhibition shown to markedly reduce neuronal plasticity and
impair vascular remodeling (Zhao et al., 2006, 2007).
Given that uncontrolled expression of MMPs can result in
tissue injury and destruction, the catalytic activity of MMPs
is regulated at four points, which are: gene expression level,
compartmentalization of the MMPs, pro-enzyme activation, and
enzyme inactivation (Ra and Parks, 2007). Cleavage of the prop-
peptide renders the MMP proteolytically active. However, given
that one cysteine residue in the pro-peptide domain coordinates
the catalytic site, disruption of this site via S-nitrosylation can
also activate MMP-9 (Gu et al., 2002; Manabe et al., 2005;
McCarthy et al., 2008). MMP is activity is further controlled
by the availability and affinity of substrates. Indeed, MMPs are
normally expressed at very low levels under normal conditions
with localized expression induced when remodeling of the ECM
is required. An in depth discussion of the transcription and
regulation of MMPs is beyond the scope of the present review;
we refer readers to some excellent reviews on the control of MMP
activity (Ra and Parks, 2007; Clark et al., 2008; Fanjul-Fernández
et al., 2010). Furthermore, MMPs are tightly regulated at both
the transcriptional and post-transcriptional level by transcription
factors and inhibitor proteins (Clark et al., 2008). In particular,
endogenous tissue inhibitors of metalloproteinases (TIMPs),
through high affinity non-covalent binding to the MMP catalytic
domain, inhibit the activity of MMPs. To date, four TIMPs have
been identified, with TIMP-1 having a specific affinity for MMP-
9 (Clark et al., 2008; Fujimoto et al., 2008). In addition, MMPs,
such as MMP-9, are secreted as inactive zymogens (proforms)
that require activation through cleavage of the pro-peptide. This
cleavage produces a conformational change, enabling a water
molecule to associate with MMP-9, rendering it proteolytically
active (Clark et al., 2008), and thereby providing another level
of control for MMP function. In particular, pro-MMP-9 may be
activated by a number of molecules including MMP-2, MMP-
3, plasmin, urokinase-type plasminogen activator (uPA), and
tPA (Rosenberg et al., 2001; Cunningham et al., 2005). Indeed,
another level of control is conferred by the influence of growth
factors, cytokines, and chemokines on both MMP and TIMP
transcription (Yan and Boyd, 2007), with a response at the
transcriptional level typically occurring within a few hours of
stimulation.
Certainly MMP-9 has been the most widely studied MMP
family member in both the experimental and clinical stroke
literature, which may in part be due to the fact that
it can easily be assessed using techniques such as gelatin
zymography. Nevertheless, the advancement of other techniques
such as multiplex ELISAs and proteome arrays has allowed the
identification and quantification of the role of other MMP family
members following stroke and their contribution to tissue injury.
MMP-9 IN EXPERIMENTAL ISCHEMIC
STROKE
Increased expression of pro/active MMP-9 has been detected
within hours to days following stroke in non-human primates
(Heo et al., 1999), rats (Romanic et al., 1998; Rosenberg et al.,
1998; Justicia et al., 2003), and mice (Fujimura et al., 1999;
Gasche et al., 1999; Asahi et al., 2001a). Following stroke,
increased levels of MMP-9 have been detected in both peripheral
and central cells including neurons, glia, endothelial cells and
neutrophils, with each of these cell types having a unique
MMP secretion/expression profile (Rosenberg, 2002; Van den
Steen et al., 2002; Gasche et al., 2006). However, the expression
of MMPs is highly dependent upon the type, duration and
severity of the ischemic insult, in addition to the animal species
and strain used, with the temporal profile of MMP expression
varying widely amongst studies. Another level of complexity in
comparison of studies is that both pro-MMP and active MMP
levels are not always reported in concert. Altogether, these issues
highlight the complexity in targeting this protease with treatment
following ischemic stroke.
Indeed, alterations in other MMPs beyond MMP-9 have
been observed following stroke. For example, increased levels
of pro/active MMPs including MMP-2 (Amantea et al., 2008;
Lenglet et al., 2014), MMP-3 (Kim et al., 2005; Si-Tayeb et al.,
2006; Yang et al., 2011; Lenglet et al., 2014), MMP-4 (Lenglet
et al., 2014), MMP-10 (Lenglet et al., 2014), and MMP-13
(Cuadrado et al., 2009). Such alterations in MMPs (and their
endogenous inhibitors) has been linked to activation of astrocytes
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andmicroglia (Kim et al., 2005; Yang et al., 2011), increased levels
of circulating inflammatory cytokines (Amantea et al., 2014) and
enhanced thrombolysis (Orbe et al., 2011).
Blood-Brain Barrier Breakdown
Disruption of the BBB is a key event in the secondary
injury cascade following stroke, one that exacerbates injury
through a number of mechanisms including permitting the
entry of peripheral immune cells into the brain to enhance the
neuroinflammatory response, and hasten the development of
vasogenic edema (Kuroiwa et al., 1985). Given their ability to
degrade the ECM and tight junction components, MMPs have
been implicated in BBB permeability alterations post-stroke.
Following stroke, a biphasic opening of the BBB is well
established (Kuroiwa et al., 1985). The first alteration in BBB
permeability occurs within hours of stroke onset, with the second
occurring some 24–48 h later (Rosenberg et al., 1998). Such early
and late alterations in barrier permeability are consistent with
the increased expression of MMP-2 and MMP-9, which are the
main MMPs that have been shown to be altered following both
stroke and traumatic brain injury (Mun-Bryce and Rosenberg,
1998; Romanic et al., 1998; Fujimura et al., 1999; Gasche et al.,
1999; Asahi et al., 2000; Planas et al., 2001; Rosenberg et al., 2001).
Specifically, in one study increased levels of MMP-2 have been
observed, in concert with an early and reversible disruption to
the BBB (Chang et al., 2003), with late BBB disruption at 24–48 h
following stroke observed in conjunction with increased MMP-
9 levels (Sandoval and Witt, 2008). The early BBB disruption
attributable to increased MMP-2 levels is deemed reversible, as
although the tight junction components loosen, they remain
within the endothelial cleft, and thus can be reassembled to
reverse such permeability changes (Yang et al., 2007). In contrast,
the delayed breach in BBB integrity in the setting of elevated
MMP-9 expression is associated with complete degradation of
the basal lamina (Mun-Bryce and Rosenberg, 1998) and tight
junction components (Asahi et al., 2001b) resulting in and gross
barrier disruption. This late barrier disruption persists for several
days and is associated with complete breakdown of the BBB
and HT (Romanic et al., 1998; Rosenberg et al., 1998; Asahi
et al., 2001b). Due to the integral function of the BBB in the
development of cerebral oedema, changes in MMP-9 levels have
also been shown to correlate with the severity of cerebral edema,
in a rodent model of stroke (Li et al., 2013). This scenario
of early MMP2 and late MMP9, however, has been challenged
by a number of other studies described below that implicate
neutrophil MMP9 in early BBB opening (Montaner et al., 2008).
In addition, despite the involvement of MMP-2 in early
barrier disruption, MMP-2 inhibition does not confer protection
against BBB disruption (Asahi et al., 2001b; Gidday et al., 2005).
Indeed, administration of the specific MMP-2/9 inhibitor SB-
3CT failed to confer protection against a hypoxic-ischemic insult
in neonatal rats (Ranasinghe et al., 2012). In contrast, MMP-
9 inhibition provides robust protection against changes in BBB
permeability (Svedin et al., 2007), suggesting that MMP-9 is the
dominant protease acting at the BBB following ischemic stroke
(Dejonckheere et al., 2011). MMP-3 immunoreactivity has been
observed in pericytes following stroke and given that MMP-3
activates MMP-9 in vivo, MMP-3 knockout mice have been
investigated to explore the effects of MMP-9 in ischemic stroke
(Gurney et al., 2006). MMP-3 knockout reduced the levels of
activeMMP-9 and subsequent BBB disruption andwas associated
with a significantly reduced number of neutrophils infiltrating
the stroke lesion.
Oxidative stress is known to play a significant role in
the evolution of injury following stroke. Through studies
in superoxide dismutase (SOD) 1-knockout mice, a role for
oxidative stress in the mediation of BBB disruption has been
revealed (Gasche et al., 2001). Specifically, higher levels of pro-
MMP-9 and active MMP-9, in conjunction with profound BBB
disruption were observed in SOD1 knockouts, an effect reversed
with MMP inhibition, with comparable findings also reported in
SOD2 knockouts (Maier et al., 2004). Subsequent studies have
revealed nitric oxide and ROS to be the specific components
of the oxidative stress response that lead to MMP-9 activation
(Gu et al., 2002), validated by the significant decrease in
infarct volume, vascular damage andMMP-9 activation following
treatment with a non-selective nitric oxide inhibitor (Gürsoy-
Ozdemir et al., 2000).
Hemorrhagic Complications
Asmany as 88% of strokes are ischemic in type and therefore may
benefit from thrombolysis with tPA to recanalize the occluded
cerebral artery (Adibhatla and Hatcher, 2008). In addition to its
actions as a thrombolytic agent, tPA, via activation of MMP-
9, may also damage the basal lamina and tight junctions of
the cerebral blood vessels, resulting in increased permeability
of the BBB, cerebral edema, and hemorrhagic complications
(Lapchak et al., 2000; Sumii and Lo, 2002). MMP-induced
degradation of the ECM is problematic as it weakens vessels,
making themmore prone to rupture and increases risk of cerebral
hemorrhage (Heo et al., 1999; Lapchak et al., 2000; Montaner
et al., 2001a; Sumii and Lo, 2002; Rosenberg and Yang, 2007;
Rosell et al., 2008). Though a number of proteases may activate
MMP-9, plasmin and tPA are two of the most important in
the setting of stroke as they have implications in hemorrhagic
complications. Indeed, such secondary disturbances to the BBB
and microvascular damage precede such HT. Thrombolysis-
induced hemorrhage is classified into two main types: PH and
HT. In PH there is a discrete loss of microvascular integrity
and extravasation of red blood cells into the brain parenchyma,
whereas HT involves gross disruption to the cerebral vasculature
and hematoma development. However, it must be noted that
tPA-induced activation of MMP-9 may be beneficial in the late
reparative phase of stroke to assist in the vascular remodeling,
angiogenesis, neurogenesis and axonal regeneration response.
In addition to driving BBB disruption, MMP-9 has also been
implicated in HT following ischemic stroke. Treatment with
tissue-type tPA increases MMP-9 levels after embolic stroke in
rodents, thereby implicating MMPs in tPA-induced hemorrhage
(Sumii and Lo, 2002). Furthermore, MMP inhibitors have been
shown to reduce the incidence and severity of tPA-induced
hemorrhagic complications (Lapchak et al., 2000; Sumii and Lo,
2002). Minocycline (either low dose IV or high dose IP) inhibited
MMP-9 upregulation induced by tPA treatment (Machado et al.,
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2009) and was shown to extend the 3 h time window for tPA
administration to 6 h in a embolic model of ischemic stroke in
rats (Murata et al., 2008).
MMP Inhibition and Knockout Studies
Reduced breakdown of the BBB has been reported with broad
inhibition of MMPs (Ferry et al., 1997; Fernandez-Patron et al.,
2001) or targeted MMP-9 gene deletion (Asahi et al., 2000;
Gasche et al., 2001; Rosenberg, 2002). Indeed, elevated active
MMP-9 was observed as early as 3 h post-stroke and peaking
at 18 h post-stroke onset, and thus preceded marked BBB
disruption at 6 h and cerebral edema at 24 h. Increased MMP-
9 levels were involved in such events as MMP inhibition with
GM6001 ameliorated BBB permeability changes and cerebral
edema (Shigemori et al., 2006). Specifically, MMP-9 knockout
animals have reduced infarct volumes, incidence of HT, volume
of cerebral edema, and functional deficits compared to wild type
animals (Romanic et al., 1998; Asahi et al., 2000, 2001b; Lee
et al., 2003; Hu et al., 2009; Wang et al., 2009). Similarly, MMP
inhibitor treatment reduced MMP-9 activation and attenuated
disorganization of tight junction proteins, including occludin and
zona-occludens-1, leading to a reduction in vascular leakage and
preservation of BBB integrity (Bauer et al., 2010). Furthermore,
MMP inhibition with GM6001 ameliorated BBB disruption at
6 h and cerebral edema at 24 h post-stroke (Shigemori et al.,
2006). Studies administering MMP inhibitors prior to stroke
have also shown benefit (Asahi et al., 2000). However, as these
molecules are unable to cross the intact BBB it is likely that they
are acting on inflammatory cells or endothelial cells, providing it
can gain access to them. The fact that such agents are beneficial
suggests that an effect on circulating leukocytes with a subsequent
reduction in MMP-9 is plausible.
MMP-9 IN CLINICAL ISCHEMIC STROKE
In keeping with the experimental literature, studies of clinical
stroke patients have revealed increased levels of MMP-9
following ischemic stroke in humans (Anthony et al., 1997;
Montaner et al., 2003b; Ning et al., 2006; Rosell et al., 2008) with
elevated MMP-9 levels observed compared to healthy controls
(Lucivero et al., 2007). Gene expression studies of peripheral
blood from stroke patients reveled that MMP-9 was one of
the key genes upregulated in response to stroke (Tang et al.,
2006). Furthermore, MMP-9 has been shown to be elevated in
the serum of stroke patients and is correlated with a worsened
outcome (Montaner et al., 2001b; Copin et al., 2005; Ning
et al., 2006). This elevation in MMP-9 was determined to
be a marker of stroke for patients arriving within 12 h of
stroke onset (Reynolds et al., 2003), with MMP-9 levels even
proposed as a marker that could predict the probability of stroke
(Lynch et al., 2004). Indeed, elevations in other MMPs, such
as MMP-10, have been observed in clinical patients following
stroke. Increased serum pro-MMP-10 levels were observed in
both tPA-treated and non-tPA-treated patients compared to
age-matched controls. Such alterations in pro-MMP-10 were
associated with large infarct volumes, development of severe
brain edema, neurological deterioration, and poor outcome at
3 months but interestingly, elevations in pro-MMP10 were not
associated with hemorrhagic transformation (Rodríguez et al.,
2013). Such studies highlight the breadth of MMP alterations
following stroke and the implications for infarct evolution and
both the development and treatment of complications.
Outcome Following Stroke
In ischemic stroke patients, a correlation between plasmaMMP-9
levels and final National Institute of Health Stroke Scale (NIHSS)
score, which is used to objectively quantify the impairment cause
be stroke, has been observed (Montaner et al., 2001b). MMP-
9 expression correlated with stroke severity and poor outcome,
as assessed by the NIHSS (Inzitari et al., 2013) at 48 h post-
stroke (Montaner et al., 2001b) but was shown to correlate with
NIHSS score early as 24 h post-stroke onset (Rosell et al., 2005).
Furthermore, there was a positive correlation between MMP-
9 levels and NIHSS score and a negative correlation with the
Barthel Index, a measure of activities of daily living (Vukasovic
et al., 2006). Although a subsequent study by Montaner showed
that highMMP-9 levels correlated withNIHSS score at admission
this did not identify a specific stroke etiology (Montaner et al.,
2008). Potential explanations for the differences in the outcomes
of these studies may include the composition of the patient
cohorts and variations in stroke size and type. In regards to long-
term outcomes, MMP-9 was associated with a poor neurological
outcome at 3 months post-stroke (Rodríguez-Yáñez et al., 2006)
and hyperacute levels of MMP-9 correlated with worse Rankin
outcome at 3 months post-stroke (Ning et al., 2006). This poor
outcome and increased levels of MMP-9 were subsequently
correlated with both infarct volume and stroke severity (Ning
et al., 2006). A single study has reported that both MMP-2 and
MMP-9 levels correlated with clinical severity and the extent of
the infarct (Sotgiu et al., 2006).
Infarct Volume
In keeping with the role of MMP-9 in hastening BBB disruption
and resultant injury, a non-significant increase in MMP-9 levels
was observed in those tPA-treated patients that developed
severe brain edema (Moldes et al., 2008). Furthermore, MMP-
9 levels were shown to directly relate to stroke infarct volume
(Horstmann et al., 2003; Rosell et al., 2005; Sotgiu et al.,
2006; Vukasovic et al., 2006), a correlation that was observed
at 24 h post-stroke (Rosell et al., 2005), but was apparent as
early as 6 h post-stroke (Montaner et al., 2003b), with MMP-
9 identified as the only marker that accurately predicted final
infarct volume (Montaner et al., 2003b). As has been observed
in the experimental stroke literature, MMP-9 levels increase over
time following clinical stroke. MMP-9 levels in ischemic stroke
patients were significantly elevated at 7d compared to 1d post-
stroke (Kurzepa et al., 2006), with a temporal profile study out to
12d post-stroke revealing that levels of MMP-9 increased steadily
over time following the onset of cerebral ischemia (Horstmann
et al., 2003).
Hemorrhagic Complications
A relationship between baseline MMP-9 levels and late HT
has been established, where high baseline levels were predictive
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of late hemorrhagic events (Montaner et al., 2001c), further
supported by the observation that MMP-9 levels were higher
in patients who developed HT of their infarct (Heo et al.,
2003). Furthermore, MMP-9 levels were significantly higher in
those patients with HT, compared to those without (Castellanos
et al., 2003). Levels of MMP-9 even differed between those
patients who developed symptomatic HT compared to non-
symptomatic HT (Castellanos et al., 2003). MMP-9 levels
were also a good predictor of petechial hemorrhage (PH)
in tPA-treated ischemic stroke patients (Castellanos et al.,
2007). Indeed, elevated MMP-9 levels were associated with
increased symptomatic intracerebral hemorrhage (ICH) or death
(Inzitari et al., 2013), leading to the suggestion that MMP
inhibitors may of clinical use when administered in conjunction
with thrombolysis to reduce or prevent such hemorrhagic
complications.
Activation of MMP-9 by tPA
tPA has been shown to directly activate MMP-9 (Wang et al.,
2003; Benarroch, 2007), with rt-PA treatment increasing MMP-
9 activity in the serum of ischemic stroke patients (Golab
et al., 2014). Such tPA-activation of MMP-9 may further
amplify the MMP-9 response to stroke and involvement in
injury pathways (Tsuji et al., 2005). Indeed, MMP-9 levels were
shown to correlate with the levels of free radicals, measured
as a marker of oxidative stress, this was observed in both
tPA-treated and non-tPA treated patients (Kelly et al., 2006).
However, tPA administration increases plasma MMP-9 levels,
with co-administration of the free radical scavenger Edaravone
having no effect on MMP-9 levels (Tsuruoka et al., 2014),
although this may have been attributable to the low-dose
Alteplase (0.6mg/kg) used. An increased rate of HT on day
1 following acute ischemic stroke was observed in patients
who underwent thrombolysis, compared to untreated controls
(Carbone et al., 2015), with thromboylsis with tPA shown to
increase venous blood levels of MMP-9 (Ning et al., 2006).
Indeed, significantly higher levels of active MMP-9 have been
observed in areas of HT, compared to both non-hemorrhagic,
and non-ischemic tissue (Rosell et al., 2008). Indeed, MMP-9
levels were higher in patients that developed HT (Castellanos
et al., 2003; Heo et al., 2003), with differences in MMP-9 levels
even observed between symptomatic and asymptomatic HT
(Castellanos et al., 2003). However, it has also been reported
that neither baseline MMP-9 levels nor the rate of MMP-
9 increase had any association with the risk of HT in the
setting of ischemic stroke (Tsuruoka et al., 2014). Clearly
this relationship requires further exploration. Nevertheless, it
has been suggested that early HT is attributable to ROS,
blood-derived MMP-9, and brain-derived MMP-2, whereas
delayed HT is likely attributable to brain-derived MMP-9 and
MMP-3, amongst other proteases, vascular remodeling and
neuroinflammation (Jickling et al., 2014). Accordingly, early
inhibition of MMP-9 may reduce hemorrhagic complications.
MMP inhibitors may maintain the integrity of the BBB following
stroke by limiting the access of tPA to brain parenchyma,
thereby reducing hemorrhagic complications (Rosenberg and
Yang, 2007).
Post-Mortem Studies
Valuable insights into the changes in MMPs following human
stroke was gained from post mortem studies of brain tissue
from stroke patients. Fresh brain tissue from ischemic and
hemorrhagic stroke patients examined within 6 h of death
revealed higher levels of MMP-9, compared to control brains
(Rosell et al., 2006). A further study by Rosell et al. (2008)
of ischemic stroke patients with hemorrhagic complications
revealed elevated MMP-9 levels within the stroke lesion. Within
the infarct core, MMP-9 was localized to perivascular tissue and
was associated with neutrophil infiltration whereas in the peri-
infarct tissue microglial cells were found to highly express MMP-
9 (Rosell et al., 2006). In hemorrhagic stroke, tissue surrounding
the hematoma was shown to have increased levels of MMP-
9. In both studies, no changes in MMP-2 levels were observed
(Rosell et al., 2006, 2008). Neutrophils were identified as the
main source of MMP-9 in areas of hemorrhage. Neutrophils were
observed surrounding microvessels in conjunction with severe
degradation of basal lamina type IV collagen and extravasation
of blood into the surrounding brain parenchyma. As such,
microvessel inflammation and MMP-9 appear to be key events
associated with the development of hemorrhagic complications
following ischemic stroke.
Overall, the clinical studies reveal that higher levels of MMP-
9 are present in patients with acute ischemic stroke, compared
with controls, and that this is a predictor for the development
of hemorrhagic complications (both PH and HT), with MMP-9
levels correlating with larger infarct volume, increasing severity
of stroke and poor functional outcome (Ramos-Fernandez et al.,
2011). In this way, MMP-9 is proposed as a marker for ongoing
brain ischemia and evolution of the stroke lesion, making it a
potential candidate for inclusion in a stroke biomarker panel. As
such, it is universally accepted that profound changes in MMP-9
expression and activity occur following ischemic stroke in both
humans and animals. However, controversy still remains as to
which cells are responsible for the bulk of the MMP-9 load
following ischemic stroke.
TIMP-1 FOLLOWING STROKE
TIMPs are the endogenous inhibitors of MMPs present under
normal conditions in tissues to regulate the activity of MMPs
(Cunningham et al., 2005). However, just as MMP-9 levels
are elevated following stroke, the expression of TIMP-1, the
endogenous inhibitor of MMP-9, has also been shown to be
dysregulated following stroke (Rivera et al., 2002). Furthermore,
the MMP-9/TIMP-1 ratio has been proposed as a marker of
stroke. Indeed, the correlation of MMP-9/TIMP-1 ratio with
cerebral edema was even stronger than that of MMP-9 alone
following ischemic stroke in rats (Li et al., 2013). Similar
findings were observed in a clinical study with the relative
increase in MMP-9/TIMP-1 ratio independently associated with
symptomatic ICH in ischemic stroke patients (Piccardi et al.,
2015). In keeping with the role of MMP-9 and TIMP-1 in the
pathogenesis of stroke, mild hypothermia provided protection
from ischemia/reperfusion injury via decreasing the expression
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ofMMP-9 (Burk et al., 2008; Zhao et al., 2013) and TIMP-1 (Zhao
et al., 2013).
Transient global cerebral ischemia led to TIMP-1 expression
within 4 h of onset within the dentate gyrus of the hippocampus
and progressed to involve other regions of the hippocampus
including CA1 by 24 h post-stroke, a region especially vulnerable
to ischemic injury. Such elevated TIMP-1 expression was
observed in conjunction with elevated MMP-9 levels at 24 h
following stroke onset (Fujimoto et al., 2008). Such increased
expression of TIMP-1 was apparent in neurons and glial cells
following global cerebral ischemia. This elevation in TIMP-1may
be a protective response to the ischemic insult to combat the
increased levels of MMP-9 in an attempt to not only preserve
endothelial barrier function but also participate in the long-
term reorganization of the tissue following injury. Although the
protective effects of TIMP-1 inhibition are thought to extend
beyond simply its inhibition of MMP-9, as neuroprotection
through TIMP-1 inhibition could not be reproduced with MMP
inhibition alone (Chesler et al., 1995).
Rendering TIMP-1 inactive abolished the neuroprotective
effects of TIMP-1 application to hippocampal cultures exposed
to an excitotoxic insult (Tan et al., 2003). TIMP-1 knockout mice
demonstrated significantly elevated Evan’s Blue extravasation,
indicative of profound BBB disruption and vasogenic edema,
along with larger infarct volumes, in keeping with increased
MMP-9 expression and activity in the absence of inhibition
by TIMP-1 (Fujimoto et al., 2008). Presumably, most of the
exogenously administered TIMPs act on endothelial cells and
circulating immune cells, such as neutrophils, to inhibit MMP-
9 activity, rather than the brain tissue itself as these molecules
are unable to cross the intact BBB. Such a hypothesis certainly
fits with the argument that neutrophils are the cellular source of
MMP-9.
CELLULAR SOURCE OF MMP-9
FOLLOWING STROKE
Increased MMP-9 levels have been well documented following
both experimental and clinical stroke. However, the cellular
source of this MMP-9, which is driving barrier permeability
changes, cerebral edema, and hemorrhagic complications
remains to be elucidated. A number of studies have sought to
investigate what cells are releasing MMP-9 in stroke, with both
peripheral and central candidates examined. A wide range of
cell types have been shown to express MMP-9 following stroke,
including neurons, microglia, and endothelial cells (Rosell et al.,
2008). However, the main or initiating source of the MMP-9
remains unclear.
Neutrophils and MMP-9
Following stroke, the chemokines and cytokines released in
response to the ischemic insult promote the chemotaxis of
inflammatory cells, such as neutrophils, to the ischemic site
(Rodrigues and Granger, 2015). These cells transmigrate into the
ischemic tissue where they contribute to tissue injury. In order to
gain access to the brain tissue, the well-orchestrated expression
of cellular adhesion molecules, integrins, and chemokines are
required to enable neutrophils to roll along the endothelium,
adhere to the endothelium and transmigrate through the
endothelial cell barrier into brain tissue (Wang and Doerschuk,
2002; Schnoor and Parkos, 2008; Alcaide et al., 2009; Choi et al.,
2009). Neutrophils are the main inflammatory cell type that
responds to the inflammatory stimulus following stroke (Tang
et al., 2006). Transmigration of neutrophils is thought to be
reliant on three proteinases released from neutrophilic granules:
neutrophil elastase (NE), collagenase, and gelatinase granules.
These proteinases act in concert to degrade the ECM and allow
passage of neutrophils into the tissue. Indeed, neutrophils are
equipped with MMP-9 in secretory granules, which enables
them to dissolving the ECM and basal lamina and “burrow”
their way into the tissue (Choi et al., 2009). However, it has
been suggested that neutrophils only require MMP-9 for stage
5 of transmigration only, where the neutrophils are migrating
between the endothelial cells (Oda et al., 1995). Nonetheless,
exocytosis of MMP-9 from gelatinase granules is likely to be
important for the transmigration of neutrophils into tissues
(Keck et al., 2002; Lee et al., 2003; Khandoga et al., 2006) with cell
culture studies demonstrating that gelatinase activity is required
for the migration of neutrophils through Matrigel and amnion
membranes (Bakowski and Tschesche, 1992; Steadman et al.,
1997). Once neutrophils gain access to the tissue they are then
able to stimulate the release/production of MMP-9 from other
cells types including resident brain cells, further perpetuating
the effects of MMP-9 activity. Indeed, neutrophil neurotoxicity
is dependent upon MMPs, reactive oxygen species (ROS) and
cytokines such as tumor necrosis factor-α (TNF-α) (Nguyen et al.,
2007).
The expression of MMP-9 by neutrophils occurs late in their
development and thus following transcription, pro-MMP-9 is
stored in cytoplasmic granules, along with neutrophil gelatinase-
associated lipocalin, which protects the pro-MMP-9 molecules
from degradation (Van den Steen et al., 2002). The presence of
pre-made MMP-9 within these neutrophil granules allows the
rapid release (within minutes) of MMP-9 into the extracellular
milieu, as opposed to the mechanism of increased expression in
other cell types that requires transcription and takes in excess
of several hours (Opdenakker et al., 2001; Van den Steen et al.,
2002). This suggests that neutrophils may be responsible for
the early increases in MMP-9 observed in plasma following
stroke. Following degranulation, pro-MMP-9 is released into the
extracellular space where it is activated through removal of its
pro-peptide by proteolysis (Opdenakker et al., 2001; Sternlicht
and Werb, 2001). Although MMP-2 is generally constitutively
expressed in most cell types, neutrophils are unique in that they
do not express MMP-2, nor do they express TIMPs.
Neutrophils as the Cellular Source of
MMP-9 Following Stroke
Inflammatory cells have been implicated as important sources of
MMP-9 in a variety of other pathological conditions including
tumor progression, asthma, and hepatic injury (Yushchenko
et al., 2000; Turba et al., 2007; Fujimura et al., 2009). Previous
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studies have suggested that neutrophils are the major source of
MMP-9 acting on the BBB (Tang et al., 2006). Indeed, MMP-
9 is expressed almost exclusively in neutrophils in peripheral
blood (Tang et al., 2006) and increased BBB permeability induced
by leukocyte-derived MMP-9 has been shown in ischemia-
reperfusion injury to correlate with peak neutrophil infiltration
(Sandoval andWitt, 2008), suggesting that neutrophils are a good
candidate to be the main source of MMP-9 released following
ischemic stroke.
Experimental Studies on MMP-9 Source
Investigation of the role of MMP-9 and neutrophils in cerebral
ischemia has taken two approaches, either knockout of MMP-9
or depletion of neutrophils prior to induction of stroke. MMP-
9 knockout significantly attenuates leukocyte recruitment into
brain tissue following stroke, implicating a pro-inflammatory
role for MMP-9 in the recruitment of leukocytes to reperfused
brain tissue (Gidday et al., 2005). Gidday et al. (2005) was the
first group to report on the cellular source of MMP-9 following
stroke but since this paper there have been a number of other
studies that have investigated whether neutrophils are the main
contributors to the increased MMP-9 load observed following
stroke. In their paper, Gidday et al. (2005) reported that depletion
of neutrophils prior to induction of stroke markedly reduced
vasogenic edema, collagen IV degradation and the extent of
cerebral infarction, suggesting the MMP-9 promotes neutrophil
transmigration into the brain and resultant injury. Such results
provide compelling evidence for neutrophils as the source of
MMP-9 following stroke.
One such study in support of the neutrophil-derived MMP-
9 theory was carried out in rats with neutropenia treatment
prior to induction of stroke to deplete neutrophils (Justicia
et al., 2003). They reported an increase in 95 kDa MMP-9 in
neutrophils and of 88 kDa MMP-9 in brain tissue following 1 h
MCAO. Neutropenia treatment prior to strokemarkedly reduced
MMP-9 expression and prevented infiltration of neutrophils
into the ischemia tissue. Treatment with an anti-intercellular
adhesion molecule-1 (expressed on endothelial and immune
cells) antibody, in addition to neutropenia, still produced low
levels of MMP-9 expression, which was attributed to expression
of MMP-9 by other cell types within the ischemic tissue.
Accordingly, this group concluded that neutrophil infiltration
was essential for the rise in MMP-9 expression and activity
observed, and that neutrophils significantly contribute to the
increase in MMP-9 in cerebral tissue through the release of
pro-MMP-9.
In contrast, a few studies have reported that neutrophils are
not the cellular source of MMP-9 following stroke (Maier et al.,
2004; Harris et al., 2005; Zozulya et al., 2008). Specifically, 3 h
MCAO was shown to produce a significant increase in MMP-
9 and MMP-2 within the ischemic hemisphere, however prior
neutrophil depletion did not affectMMP-9 protein levels, nor was
there any benefit in terms of infarct volume, HT, cerebral edema,
or functional outcome as measured by the neuroscore (Harris
et al., 2005). Accordingly, this group proposed that neutrophils
are not an important contributor to MMP-9 expression in the
setting of cerebral ischemia and do not have a significant effect
on neurovascular damage or neurological function and therefore
is unlikely to be a key player in early microvascular damage and
hemorrhagic complications following stroke. They suggest that
neutrophils may be more important in ischemia models where
there is a lower degree of injury, certainly the 3 h MCAO used
in this study is at the severe end of the ischemia spectrum.
Maier et al. (2004) found MMP-9 expression to be variable
within the ischemic hemisphere and proposed that various
cell types contribute differently in a region dependent manner.
All myeloperoxidase (MPO, major component of neutrophil
azurophilic granules)-positive cells were found to be MMP-9-
postive and these cells were present in high numbers. Micgroglia
were also shown to express MMP-9, but not all microglia were
MMP-9 positive. MMP-9 immunoreactivity was clearly visible
in vessels demonstrating Evan’s blue extravasation. However,
they did not observe any difference in the number of MPO
positive cells over time, from the 24–72 h time-points, nor
between the wild type of SOD2 animals examined. Furthermore,
the MMP-9 response was shown to be bi-phasic, which did
not coincide with neutrophil infiltration into the stroke lesion.
Although not discounting the contribution of neutrophil-derived
MMP-9 in barrier disruption and evolution of injury following
stroke, this group suggest that neutrophils are not the primary
source of MMP-9 following stroke and that other cell types
such as microglia, astrocytes, and endothelial cells may be more
appropriate targets for MMP inhibition. Such findings suggest
that neutrophils may be the cells that initiate the release of MMP-
9 in/directly from these other cell types, thereby potentiating
MMP-9 release within ischemic tissue. As such, neutrophils may
release MMP-9 locally at the BBB and do not need to migrate
into the brain parenchyma to initiate the release of MMP-
9 from resident brain cells to perpetuate the injury cascade.
Indeed, studies of cultured endothelial cells showed that under
normal conditions neutrophils weakly express MMP-9 but when
co-cultured with pericytes an increase in MMP-9 secretion is
observed, indicating that pericytes may be responsible for the
increase in MMP-9 (Zozulya et al., 2008).
Neutrophils themselves are a significant source of ROS
(Rodrigues and Granger, 2015). In a cell culture model, using
neutrophil conditionedmedium, neutrophils were shown to have
high MMP-9 expression and release high levels of superoxide,
hydrogen peroxide, and TNF-α (Nguyen et al., 2007). Treatment
of the cells with the MMP-9 inhibitor GM6001 produced an
80% reduction in MMP-9 activity and an accompanying decrease
in hydrogen peroxide and increase in TNF-α. Such findings
indicate the neutrophil-derived MMP-9 can promote cell death
by increasing the levels of ROS and also through the regulation
of NE that increases endothelial cell death.
Clinical Studies on MMP-9 Source
Gene expression analysis of peripheral blood taken from
ischemic stroke patients revealed that MMP-9 was significantly
upregulated in neutrophils early after stroke (Tang et al., 2006). A
human study measuring MMP-9 levels in the CSF and serum of
controls and patients with various neurological disorders showed
that MMP-9 was not expressed in the CSF of controls but was
markedly increased in the CSF of patients. This increase in
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MMP-9 was attributable to an increased in neutrophils within the
CSF (Yushchenko et al., 2000), whereas monocytes/macrophages
and lymphocytes were only shown to be weak producers of
MMP-9.
Not only have neutrophils been implicated as a source of
MMP-9 following stroke which contributes to injury and barrier
dysfunction, they have also been suggested to be the source of
MMP-9 following tPA treatment. This was supported by the
observation that tPA treatment can induce the release of pro-
MMP-9 from ischemic brain (Justicia et al., 2003) and more
recent observations that tPA can directly initiate the release
of MMP-9 (Cuadrado et al., 2008), along with other MMPs
and TIMPs. Given that tPA promotes neutrophil degranulation
and the release of MMP-9. These inflammatory cells are good
candidates to be the main source of MMP-9 post-stroke in
the setting of tPA treatment, and may be responsible, at least
in part, for tPA-induced hemorrhage (Cuadrado et al., 2008).
In thrombolysed ischemic stroke patients a peak of neutrophil
degranulation was observed 30min following tPA administration
(Carbone et al., 2015). The tPA-induced degranulation of
neutrophils induced a combined release of the contents from
primary (MPO and NE), secondary (collagenases such as MMP-
8) and tertiary granules (MMP-9) (Carbone et al., 2015). Such
increases in MMP-9 were seen in microvessels and neutrophils
associated with the hemorrhagic tissue. Neutrophils were found
to be an important source of MMP-9, as indicated by MPO
staining, with total brain MMP-9 levels correlating with the
number of MMP-9 positive neutrophils. In terms of HT, it
appears that it is not the neutrophils adhered to the endothelium
but rather those that transmigrate into the cerebral tissue that are
responsible for such hemorrhagic complications (Gautier et al.,
2009). As such, the location of the neutrophils, for example
neutrophils within the cerebral vasculature, those localized to
the BBB or neutrophils that have extravasated into the brain
parenchyma, may determine the effect of MMP-9 release on the
local tissue. However, others have suggested that neutrophils are
not necessary for the acute development of HT (Harris et al.,
2005). Human brain endothelial cells were shown to participate
in MMP-mediated BBB breakdown during an ischemic insult,
although their data did not support a role of MMP-9 in this
process. Instead, MMP-2 was identified as the MMP that was
elevated in ischemia.
COMPARISON BETWEEN EXPERIMENTAL
AND CLINICAL DATA
The experimental and clinical literature is in agreeance that
profound elevations in MMP-9 occur early following stroke
that can hasten and exacerbate injury. Specifically, in the
experimental studies, elevations in MMP-9 are observed as early
as 3 h following stroke (Shigemori et al., 2006) and persist for
days following stroke onset. Such alterations in MMP-9 are
associated with increased BBB permeability (Romanic et al.,
1998; Rosenberg et al., 1998; Asahi et al., 2001b; Sandoval and
Witt, 2008), the development of cerebral edema (Li et al., 2013),
hemorrhagic transformation (Romanic et al., 1998; Rosenberg
et al., 1998; Asahi et al., 2001b; Sandoval and Witt, 2008),
increased infarct volume (Romanic et al., 1998; Asahi et al., 2000,
2001b; Lee et al., 2003; Hu et al., 2009; Wang et al., 2009; Li
et al., 2013), and poor outcomes (Romanic et al., 1998; Asahi
et al., 2000, 2001b; Lee et al., 2003; Hu et al., 2009; Wang et al.,
2009; Li et al., 2013) in animal models. Indeed, the clinical
studies report a comparable picture with MMP-9 levels elevated
as early as 6 h post-stroke in post-mortem tissue (Rosell et al.,
2006) and within 12 h in patients (Reynolds et al., 2003) with
such alterations and persisting for many days thereafter with
these changes associated with large infarct volumes (Horstmann
et al., 2003; Rosell et al., 2005; Sotgiu et al., 2006; Vukasovic
et al., 2006), hemorrhagic transformation of the infarct (both
with and without tPA treatment), and poor outcomes (Rosell
et al., 2005; Ning et al., 2006; Rodríguez-Yáñez et al., 2006;
Vukasovic et al., 2006) in clinical stroke patients. Furthermore,
the experimental and clinical literature also largely agree that
neutrophils are the source of MMP-9 (Yushchenko et al., 2000;
Justicia et al., 2003; Gidday et al., 2005; Cuadrado et al., 2008;
Gautier et al., 2009) which is contributing to hastening of the
ischemic injury including infarct extension and the development
of complications such as hemorrhagic transformation.
CONCLUSIONS
We propose a likely model to explain the sequential breakdown
and repair of the BBB following stroke (Figure 1). Early after
stroke (12–48 h) neutrophils adhere to the cerebrovascular
endothelium where they release MMP-9 that degrades the basal
lamina of the endothelial cells and astrocytes. This enables
migration of neutrophils into the ischemic tissue and subsequent
opening of the BBB results in the formation of cerebral edema.
At the ischemic core, MMP-9 may be released by both infiltrating
neutrophils and resident microglia. Neutrophil-derived MMP-
9 degrades the BBB, whilst the microglia-derived MMP-9 acts
in concert with other molecules to produce neuronal and
glial cell death and microglia likely undergo apoptosis in
this environment. Upon restoration of blood flow, repair of
the BBB may be initiated at the margins of the infarction.
At this stage, all cells, including endothelial cells, glia, and
neurons, may release MMPs and other proteases at low levels
in order to remodel the basement membrane and restore cell-
cell contacts to allow for angiogenesis and gliogenesis to occur
in order to re-establish the BBB. Therefore, manipulation of
the MMP-TIMP system following stroke needs to be well
orchestrated to prevent tissue injury early but also assist in
tissue remodeling late after the event and the therapeutic
window available to limit BBB destruction following stroke is
quite short, after which reparative functions would need to
predominate.
In conclusion, a number of experimental studies suggest
that neutrophils are in fact the main cellular course of MMP-
9 following stroke (not resident brain cells) and that these cells
use MMP-9 to transmigrate into ischemic tissue, contribute
to ischemic injury in the form of ECM degradation, BBB
permeability changes, vasogenic edema, and HT, whilst also
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FIGURE 1 | The role of MMP-9 in exacerbating injury pathways in ischemic stroke. MMP-9 released from neutrophils allows these cells to transmigrate into
the brain tissue, where they release MMP-9 and other deleterious agents such as ROS, thereby stimulating the release of MMP-9 from resident brain cells and
contributing to the cell injury and cell death pathways. Neutrophil-derived MMP-9 actively degrades components of the BBB leading to the development of cerebral
edema and hemorrhagic transformation, both of which worsen stroke severity, lead to infarct extension and increase the risk of death and disability post-stroke.
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stimulating the release of MMP-9 from resident brain cells such
as neurons and microglia. Clearly, the interaction of action
of leukocytes at the BBB following stroke requires further
investigation to elucidate the contribution of neutrophil-derived
to ECM degradation, BBB disruption and subsequent vasogenic
edema, hemorrhage and parenchymal injury.
Many studies have focused on the protection of neurons as a
therapeutic target. However, given that such a small percentage
of all cells in the brain are neurons it seems more appropriate
to consider protection across many cell types. Accordingly,
investigation of the neurovascular unit and the complex
interplay of endothelial cells, pericytes, astrocytes, and infiltrating
leukocytes is likely to yield more appropriate therapeutic targets.
Information regarding the relationship between MMP-9 and
neutrophils may facilitate understanding of the mechanisms
involved in BBB breakdown following stroke and ultimately
guide therapeutic intervention.
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